(Q24200228)

inferred from title

author

Eduardo Nobile-Orazio

3

object named as

Eduardo Nobile-Orazio

0 references

author name string

T Umapathi

1

0 references

Richard AC Hughes

2

0 references

Jean-Marc Léger

Cochrane Database of Systematic Reviews

4

0 references

publication date

18 April 2012

0 references

published in

0 references

cites work

Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Mycophenolate mofetil and its mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Long term follow up of multifocal motor neuropathy with conduction block under treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Mycophenolate mofetil in dysimmune neuropathies: a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Multifocal motor neuropathy with conduction block misdiagnosed as multiple entrapment neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Bilateral phrenic neuropathy as a presenting feature of multifocal motor neuropathy with conduction block

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Multifocal motor neuropathy with conduction block: a study of 24 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Multifocal motor neuropathy: response to human immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

An open-label trial of rituximab (Rituxan®) in multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Mycophenolate mofetil for myasthenia gravis: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Plasmapheresis in multifocal motor neuropathy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Clinical and neurophysiological assessment of immunoglobulin therapy in five patients with multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Electrophysiological improvement after intravenous immunoglobulin in motor neuropathy with multifocal conduction block

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

An open label clinical trial of complement inhibition in multifocal motor neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

The clinical and diagnostic role of anti-GM1 antibody testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

A syndrome of asymmetric limb weakness with motor conduction block

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Multifocal motor neuropathy with conduction block: is it a distinct clinical entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Chronic motor neuropathies: response to interferon-beta1a after failure of conventional therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Mycophenolate Mofetil for Myasthenia Gravis A Double‐Blind, Placebo‐Controlled Pilot Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Multifocal motor neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Adult Norms for a Commercially Available Nine Hole Peg Test for Finger Dexterity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Multifocal motor neuropathy without overt conduction block

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Treatment of IgM antibody associated polyneuropathies using rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Mycophenolate mofetil treatment in resistant myositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

A computer simulation of conduction block: effects produced by actual block versus interphase cancellation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Beneficial effect of rituximab monotherapy in multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

The sensitivity and specificity of anti-GM1 antibody testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

How long is IVIg effective in multifocal motor neuropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Mycophenolate in treatment-resistant inflammatory neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Criteria for conduction block based on computer simulation studies of nerve conduction with human data obtained in the forearm segment of the median nerve

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Intravenous immunoglobulin for multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Interobserver agreement for the assessment of handicap in stroke patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Immunosuppressive treatment for multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Motor Neuropathy with Proximal Multifocal Persistent Conduction Block, Fasciculations and Myokymia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Multifocal motor neuropathy: Is conduction block essential?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

Immunosuppressive treatment of motor neuron syndromes. Attempts to distinguish a treatable disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Immunosuppressive treatment in multifocal motor neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Pathological findings at the site of conduction block in multifocal motor neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Sensory nerve pathology in multifocal motor neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Consensus criteria for the diagnosis of multifocal motor neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Motor neuropathy with multifocal conduction blocks

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Conduction block in clinical practice

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Multifocal motor neuropathy presenting as ophthalmoplegia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Upper limb predominant, multifocal chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Multifocal motor neuropathy and Lewis Sumner syndrome: two distinct entities

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Multifocal motor neuropathy and Lewis Sumner syndrome: a clinical spectrum

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

AAEM news and comments

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Natural history of 46 patients with multifocal motor neuropathy with conduction block

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Multifocal motor neuropathy: clinical and electrophysiological findings

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Efficacy of cyclosporine treatment in multifocal motor neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Intravenous immunoglobulin treatment in multifocal motor neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Multifocal motor neuropathy mimicking motor neuron disease: nine cases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

79(th) ENMC International Workshop: multifocal motor neuropathy. 14-15 April 2000, Hilversum, The Netherlands

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Multifocal motor neuropathy and asymptomatic Hashimoto's thyroiditis: first report of an association

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Multifocal motor neuropathy during treatment with infliximab

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Circulating levels of cytokines and their modulation by intravenous immunoglobulin in multifocal motor neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Interferon beta-1a as adjunctive treatment for multifocal motor neuropathy: an open label trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Oral methotrexate as adjunctive therapy in patients with multifocal motor neuropathy on chronic IVIg therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Chronic acquired demyelinating motor neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

No benefit of treatment with cyclophosphamide and autologous blood stem cell transplantation in multifocal motor neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Mycophenolate mofetil for chronic inflammatory demyelinating polyradiculoneuropathy: An open-label study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Acute neuropathy with multiple conduction blocks after TNFalpha monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Multifocal motor neuropathy with and without conduction block: A single entity?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Multifocal motor neuropathy: the diagnostic spectrum and response to treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Multifocal demyelinating neuropathy with persistent conduction block

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Slow resolution of multifocal weakness and fasciculation: a reversible motor neuron syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Multifocal motor neuropathy with conduction block after Campylobacter jejuni enteritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Pulsed high-dose dexamethasone is not effective in patients with multifocal motor neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Magnetic resonance imaging of the brachial plexus in patients with multifocal motor neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Multifocal motor neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Deterioration of multifocal motor neuropathy after plasma exchange

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Multifocal inflammatory demyelinating neuropathy: a distinct clinical entity?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Treatment of multifocal motor neuropathy with interferon-beta1A

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021

Multifocal inflammatory demyelinating neuropathy: A distinct clinical entity?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003217.PUB4

7 January 2021